New-onset cutaneous lupus erythematosus after the COVID-19 vaccine.
Dermatol Online J
; 27(11)2021 Nov 15.
Article
in English
| MEDLINE | ID: covidwho-1675050
ABSTRACT
Vaccine development for COVID-19 has progressed expeditiously. To date, the Food and Drug Administration (FDA) has authorized the Moderna/mRNA-1273, Pfizer-BioNTech (BNT162b2), and Johnson & Johnson's Janssen (JNJ-78436735) vaccines for use in the United States. Immediate side effects have included myalgia fatigue, chills, fever, and headache. We report an elderly patient with a history of lung cancer and no prior history of autoimmune disease who developed cutaneous lupus erythematosus two ½ months after the second dose of the Pfizer-BioNTech COVID-19 vaccine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lupus Erythematosus, Cutaneous
/
BNT162 Vaccine
/
Lung Neoplasms
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal subject:
Dermatology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS